Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharming Group has formed partnership with an Israeli pharmaceutical company, MegaPharm to commercialize Ruconest (recombinant human C1 inhibitor) as a treatment for acute angioedema attacks in patients with hereditary angioedema (HAE) in Israel.
Subscribe to our email newsletter
As per the terms of the agreement, Pharming is entitled to receive certain commercial, regulatory and clinical milestones from MegaPharm.
MegaPharm will buy its commercial supply of Ruconest from Pharming at a supply price, based on a percentage of net sales of Ruconest.
MegaPharm expects to launch Ruconest in 2012.
Pharming CEO Sijmen de Vries they are pleased to have taken a another step towards making Ruconest available to HAE patients globally.